ArticleCNS neuroscience & therapeutics2026
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Cerebral Cortical Encephalitis: A Comparative Study With Antibody-Negative and Non-MOG Antibody-Positive Cortical Encephalitis in Chinese Adults.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo investigate the clinical, radiological, and prognostic characteristics of autoimmune cortical encephalitis associated with different autoantibodies in Chinese adults, and to compare the features of myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis (MOG-CCE) with antibody-negative and non-MOG antibody-positive autoimmune cortical encephalitis.
methodsA retrospective study was conducted on 120 adult patients diagnosed with autoimmune cortical encephalitis at the Second Xiangya Hospital, Central South University, from 2014 to 2024. Patients were divided into three subgroups: the antibody-negative group, the non-MOG antibody-positive group, and the MOG-CCE group. Clinical, radiological, and therapeutic characteristics were analyzed, and logistic regression was performed to identify predictors of poor prognosis.
resultsMOG-CCE accounted for 18.3% of all autoimmune cortical encephalitis cases. Compared with other subtypes, MOG-CCE was characterized by seizure-dominant clinical presentation and unilateral cortical MRI lesions. Patients with MOG-CCE responded favorably to immunotherapy and exhibited lower recurrence and disability rates. In contrast, antibody-negative and non-MOG antibody-positive autoimmune cortical encephalitis showed more severe neuropsychiatric symptoms and poorer outcomes. A higher peak mRS score was the strongest independent predictor of long-term disability.
conclusionsMOG-CCE represents a distinct clinical phenotype within autoimmune cortical encephalitis, with favorable immunotherapy responsiveness and prognosis. Antibody profiling aids in disease classification and prognostic evaluation. Prospective multicenter studies are warranted to elucidate underlying mechanisms and refine individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.